肝肺综合征药物治疗的研究进展  

Research in progress pharmacological treatment on hepatopulmonary syndrome

作　　者：高静[1] 曾子洋[1] 易斌[1] 鲁开智[1] GAO Jing ZENG Ziyang YI Bin LU Kaizhi(Department of Anesthesia, Southwest Hospital, the Third Military Medical University, Chongqing 400038, Chin)

机构地区：[1]第三军医大学西南医院手术麻醉科,重庆400038

出　　处：《麻醉安全与质控》2017年第4期212-216,共5页Perioperative Safety and Quality Assurance

基　　金：国家自然科学基金(81170053;81170414)

摘　　要：肝肺综合征(HPS)是一种以低氧血症为主要表现的临床综合征,高发于肝硬化患者,常常导致围术期严重肺部并发症,目前研究证实其病理机制复杂,临床治疗效果受限,只有行原位肝移植能得到缓解。因此针对HPS的病理生理基础,寻找确切有效的药物治疗是未来解决HPS临床难题的方向。Hepatopulmonary syndrome （HPS） seen in patients with liver cirrhosis is characterized with remarkable hypoxemia and results in serious perioperative pulmonary complications. The mechanisms of theses complications are complex and less clear; therefore, no effective treatment is available other than orthotropic liver transplant. To explore the pathophysiological mechanism and effective regimen for lIPS are the future direction of clinical management in this disease.

关 键 词：肝肺综合征 病理机制 药物治疗 

分 类 号：R563[医药卫生—呼吸系统] R575.2[医药卫生—内科学]